TIVDAK (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global...
BOTHELL, Wash., & COPENHAGEN, Denmark--(BUSINESS WIRE)--Oct 22, 2023--
BOTHELL, Wash., & COPENHAGEN, Denmark--(BUSINESS WIRE)--Oct 22, 2023--